Preformulation Studies of Ibudilast: Physicochemical Characterization and Compatibility Assessment with Bovine Serum Albumin
International Journal of Drug Delivery Technology · 01.06.2026 · 16 (41s)
DOI: 10.25258/ijddt.16.41s.150 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 01.06.2026. Verfasst von Suraj Vishwas und 2 weiteren Autor:innen.
Abstract (Originalsprache)
This study presents comprehensive preformulation investigations of Ibudilast, a phosphodiesterase inhibitor with therapeutic applications in bronchial asthma, cerebrovascular disorders, multiple sclerosis, and substance use disorders. The research aimed to establish a scientific foundation for rational formulation development by systematically characterizing Ibudilast's physicochemical properties. Organoleptic evaluation confirmed Ibudilast as a white, odorless, bitter, crystalline powder. FT-IR spectroscopy validated the drug's identity through characteristic absorption bands at 3083 cm⁻¹ (aromatic C-H), 2959 cm⁻¹ (aliphatic C-H), 1640 cm⁻¹ (C=O carbonyl), and 1538 cm⁻¹ (aromatic C=C/C=N), confirming the pyrazolopyridine ring structure with isopropyl and isobutyryl substituents. UV spectrophotometry established λmax at 227 nm in methanol. The melting point was determined to be 58-62°C, with slight deviation from literature values (54-58°C), confirming drug purity. Miscibility studies revealed poor water miscibility with complete dissolution in methanol and ethanol within 2-4 minutes. Micromeritic evaluation demonstrated passable flow properties with Carr's Index of 23.19 ± 1.24%, Hausner's Ratio of 1.30 ± 0.04, and angle of repose of 36.45 ± 1.82°. FT-IR compatibility studies with bovine serum albumin demonstrated no chemical incompatibility with only minimal peak shifts (2-4 cm⁻¹), indicating weak physical interactions and confirming BSA's suitability as a carrier for nanoparticle formulation. Optical microscopy revealed irregular crystalline particles with a mean size of 48.35 ± 12.67 μm, suggesting potential benefits from particle size reduction strategies. These comprehensive preformulation data provide essential insights for developing optimized Ibudilast formulations with enhanced bioavailability and therapeutic efficacy.
Zitieren
APA
Vishwas, S., Paul, S. D., & Sahu, A. K. (2026). Preformulation Studies of Ibudilast: Physicochemical Characterization and Compatibility Assessment with Bovine Serum Albumin. International Journal of Drug Delivery Technology, 16(41s). https://doi.org/10.25258/ijddt.16.41s.150
Vancouver
Vishwas S, Paul SD, Sahu AK. Preformulation Studies of Ibudilast: Physicochemical Characterization and Compatibility Assessment with Bovine Serum Albumin. International Journal of Drug Delivery Technology. 2026;16(41s). doi:10.25258/ijddt.16.41s.150
BibTeX
@article{Vishwas2026,
author = {Vishwas, Suraj and Paul, Swarnali Das and Sahu, Anil Kumar},
title = {Preformulation Studies of Ibudilast: Physicochemical Characterization and Compatibility Assessment with Bovine Serum Albumin},
journal = {International Journal of Drug Delivery Technology},
year = {2026},
volume = {16},
number = {41s},
doi = {10.25258/ijddt.16.41s.150}
}
EUVIMED